FDA Determines Regulatory Review Period for EDWARDS SAPIEN 3 TRANSCATHETER PULMONARY VALVE

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for patent extension of the EDWARDS SAPIEN 3 TRANSCATHETER PULMONARY VALVE, following submissions to the US Patent and Trademark Office (USPTO).